Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 200 Total
SPGC - Sacks Parente Golf Inc - Stock Price Chart
TickerSPGC [NASD]
CompanySacks Parente Golf Inc
CountryUSA
IndustryLeisure
Market Cap5.85MEPS (ttm)-0.32
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S16.73EPS next 5Y-
P/B1.01EPS Q/Q-251.96%
Dividend-Sales Q/Q254.55%
Insider Own58.64%Inst Own0.77%
Insider Trans0.00%Inst Trans-
Short Float1.43%Earnings-
Analyst Recom-Target Price-
Avg Volume62.49K52W Range0.46 - 30.00
Sacks Parente Golf, Inc. is a technology-forward golf company. It engages in the provision of golf products including putting instruments, golf shafts, golf grips, and other golf-related products. The company was founded by Steve Sacks, Richard Parente, Timothy L. Triplett, and Akinobu Yorihiro in March 2018 and is headquartered in Camarillo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoge Brett WidneyDirectorOct 16 '23Buy1.097,6208,306255,400Oct 16 05:28 PM
Hoge Brett WidneyDirectorOct 13 '23Buy1.0922,38024,394247,780Oct 16 05:28 PM
Hoge Brett WidneyDirectorAug 31 '23Buy2.4230,00072,600225,400Aug 31 05:48 PM
HEPA - Hepion Pharmaceuticals Inc - Stock Price Chart
TickerHEPA [NASD]
CompanyHepion Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap7.71MEPS (ttm)-12.32
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y63.67%
P/S-EPS next 5Y-
P/B1.22EPS Q/Q7.17%
Dividend-Sales Q/Q-
Insider Own1.42%Inst Own13.65%
Insider Trans6.88%Inst Trans-42.30%
Short Float1.17%Earnings-
Analyst Recom3.00Target Price22.00
Avg Volume76.71K52W Range1.49 - 20.66
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijngaard PeterDirectorNov 27 '23Buy3.052,5007,6259,501Nov 28 06:55 AM
Wijngaard PeterDirectorNov 24 '23Buy3.092,5007,7257,001Nov 28 06:55 AM
Wijngaard PeterDirectorSep 19 '23Buy5.641,0005,6404,501Sep 20 11:27 AM
Foster Robert TCEO and DirectorSep 18 '23Buy5.601,6008,96050,470Sep 19 09:01 AM
Wijngaard PeterDirectorSep 15 '23Buy5.602,00011,2013,501Sep 20 11:27 AM
SBFM - Sunshine Biopharma Inc - Stock Price Chart
TickerSBFM [NASD]
CompanySunshine Biopharma Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap1.43MEPS (ttm)-19.05
P/E-EPS this Y115.79%
Forward P/E0.08EPS next Y466.67%
PEG-EPS past 5Y73.50%
P/S0.06EPS next 5Y-
P/B0.02EPS Q/Q94.97%
Dividend-Sales Q/Q94.94%
Insider Own4.14%Inst Own11.83%
Insider Trans292.78%Inst Trans-
Short Float0.74%EarningsMar 28/b
Analyst Recom1.00Target Price300.00
Avg Volume546.93K52W Range1.73 - 140.00
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Slilaty Steve N.Chief Executive OfficerMar 04 '24Buy0.10100,00010,000130,000Mar 05 04:05 PM
Slilaty Steve N.Chief Executive OfficerFeb 08 '24Buy0.1020,0002,00030,000Feb 12 04:05 PM
SHIM - Shimmick Corp. - Stock Price Chart
TickerSHIM [NASD]
CompanyShimmick Corp.
CountryUSA
IndustryEngineering & Construction
Market Cap57.55MEPS (ttm)-
P/E-EPS this Y-143.75%
Forward P/E4.25EPS next Y352.38%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.81EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own92.55%Inst Own9.12%
Insider Trans0.00%Inst Trans-
Short Float2.05%EarningsMar 28/b
Analyst Recom1.00Target Price9.50
Avg Volume29.37K52W Range2.59 - 7.99
Shimmick Corp. engages in the provision of water and other critical infrastructure solutions. The company was founded in 1990 and is headquartered in Irvine, CA.
TFFP - Tff Pharmaceuticals Inc - Stock Price Chart
TickerTFFP [NASD]
CompanyTff Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap6.50MEPS (ttm)-12.68
P/E-EPS this Y54.77%
Forward P/E-EPS next Y4.66%
PEG-EPS past 5Y-13.86%
P/S-EPS next 5Y-
P/B0.64EPS Q/Q60.48%
Dividend-Sales Q/Q-
Insider Own0.00%Inst Own15.29%
Insider Trans-Inst Trans11.89%
Short Float3.44%EarningsMar 28/a
Analyst Recom1.00Target Price24.50
Avg Volume30.25K52W Range3.00 - 21.25
Apr-15-24 07:00AM TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions (GlobeNewswire) -8.57%
Mar-28-24 10:54PM TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.35%
04:05PM TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-27-24 04:01PM TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs (GlobeNewswire)
Mar-25-24 09:01AM TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting (GlobeNewswire)
Mar-22-24 03:11PM TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -6.33%
Mar-20-24 12:00PM TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -10.37%
09:03AM TFF Pharmaceuticals Announces Update on Clinical Programs (GlobeNewswire)
Mar-14-24 04:47PM TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference March 17-19, 2024 (GlobeNewswire)
Jan-24-24 08:00AM TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference (GlobeNewswire) +10.88%
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARLSON CAPITAL L P10% OwnerAug 16 '23Sale0.391,0003925,064,000Aug 17 05:29 PM
Weisman Harlan FPresident and CEOAug 15 '23Buy0.25600,000150,000814,615Aug 15 08:00 AM
Mikhak ZamanehChief Medical OfficerAug 15 '23Buy0.25120,00030,000135,000Aug 15 08:00 AM
MILLS ROBERT SDirectorAug 15 '23Buy0.2540,00010,00055,980Aug 15 08:00 AM
ROCAMBOLI STEPHENDirectorAug 15 '23Buy0.2520,0005,00036,000Aug 15 08:00 AM
GRI - GRI Bio Inc - Stock Price Chart
TickerGRI [NASD]
CompanyGRI Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap1.47MEPS (ttm)-63.58
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y26.64%
P/S-EPS next 5Y-
P/B1.15EPS Q/Q87.41%
Dividend-Sales Q/Q-
Insider Own6.23%Inst Own0.86%
Insider Trans0.00%Inst Trans7.63%
Short Float1.81%EarningsApr 01/b
Analyst Recom1.00Target Price2520.00
Avg Volume752.05K52W Range0.50 - 115.50
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
MGAM - Mobile Global Esports Inc. - Stock Price Chart
TickerMGAM [NASD]
CompanyMobile Global Esports Inc.
CountryUSA
IndustryElectronic Gaming & Multimedia
Market Cap0.72MEPS (ttm)-0.32
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S144.66EPS next 5Y-
P/B0.23EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own18.38%Inst Own5.57%
Insider Trans0.00%Inst Trans-
Short Float1.16%Earnings-
Analyst Recom3.00Target Price1.00
Avg Volume3.00M52W Range0.04 - 0.99
Mobile Global Esports, Inc. is an esports and social platform company, which engages in holding trademark and intellectual property rights for collegiate esports tournaments, teams, and players. It focuses on the development of esports. The company was founded by David Pross and Kenin M. Spivak on March 11, 2021 and is headquartered in Westport, CT.
BPTS - Biophytis ADR - Stock Price Chart
TickerBPTS [NASD]
CompanyBiophytis ADR
CountryFrance
IndustryBiotechnology
Market Cap2.39MEPS (ttm)-3.52
P/E-EPS this Y-100.00%
Forward P/E-EPS next Y0.00%
PEG-EPS past 5Y51.26%
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.05%
Insider Trans-Inst Trans-62.93%
Short Float4.28%Earnings-
Analyst Recom3.00Target Price4.04
Avg Volume341.41K52W Range0.27 - 4.22
Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and Rene Lafont on September 27, 2006 and is headquartered in Paris, France.
CDTX - Cidara Therapeutics Inc - Stock Price Chart
TickerCDTX [NASD]
CompanyCidara Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap46.57MEPS (ttm)-0.38
P/E-EPS this Y-150.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y33.09%
P/S0.82EPS next 5Y-
P/B5.78EPS Q/Q-153.52%
Dividend-Sales Q/Q-68.79%
Insider Own9.96%Inst Own29.71%
Insider Trans-0.89%Inst Trans0.69%
Short Float0.24%EarningsApr 22/a
Analyst Recom1.00Target Price4.50
Avg Volume697.34K52W Range0.59 - 1.48
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tari LeslieCHIEF SCIENTIFIC OFFICERMar 11 '24Sale0.6721,02914,085258,681Mar 12 09:48 PM
Sandison TaylorChief Medical OfficerMar 11 '24Sale0.6720,66213,839347,095Mar 12 09:47 PM
Ward ShaneCOO & CLOMar 11 '24Sale0.6720,47313,713198,770Mar 12 09:46 PM
Shah PreetamCFO & CBOMar 11 '24Sale0.6718,93112,680227,210Mar 12 09:45 PM
Sandison TaylorChief Medical OfficerSep 11 '23Sale0.9518,79317,810363,757Sep 13 04:22 PM
AIRE - reAlpha Tech Corp. - Stock Price Chart
TickerAIRE [NASD]
CompanyreAlpha Tech Corp.
CountryUSA
IndustryReal Estate Services
Market Cap26.53MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.14EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own75.98%Inst Own1.02%
Insider Trans0.00%Inst Trans-
Short Float4.85%Earnings-
Analyst Recom-Target Price-
Avg Volume1.13M52W Range0.67 - 575.41
reAlpha Tech Corp. operates as an AI-powered real estate technology and investment company. It engages in the business of identification, acquisition, financing, marketing and management of short-term rental properties for the benefit of the company's members and stockholders. The company was founded by Giri Devanur on November 30, 2020 and is headquartered Dublin, OH.
1234561020